Clinical Trials Directory

Trials / Unknown

UnknownNCT05364996

Alveolar and Serum sRAGE in Severe Asthma in Children

Cross-sectional Pilot Study of the Alveolar and Serum sRAGE Biomarker in Severe Asthma in Children.

Status
Unknown
Phase
Study type
Observational
Enrollment
85 (estimated)
Sponsor
University Hospital, Clermont-Ferrand · Academic / Other
Sex
All
Age
1 Day – 16 Years
Healthy volunteers
Not accepted

Summary

sRAGE is a recognized marker of alveolar injury in acute respiratory distress syndrome (ARDS). More recently, it seems to be an interesting marker in asthma. It is the soluble form of the pro-inflammatory RAGE receptor overexpressed in the lungs and in particular the bronchi. It acts as a decoy to its ligands, and thus blocks the pro-inflammatory axis of RAGE. Few studies are available in asthma, especially in children. A local study showed low levels of serum sRAGE in the context of acute bronchiolitis. The same finding emerges from the few studies available in asthma, with rates all the lower when the asthma is poorly controlled. A study carried out in the animal model in 2012 found an absence of inflammatory infiltrate, the absence of increased expression of mucin and the absence of mucus goblet cell hyperplasia within the respiratory epithelium in the absence of RAGE receptor in sensitized mice dust mites, after exposure to their allergen. One could imagine in the long term a potential therapeutic avenue by a substitution in sRAGE in this pathology. The objective of this study is to study the ability of the alveolar sRAGE level measured on broncho-alveolar lavage for assessment, to discriminate the clinical degrees of control of severe asthma in children.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTbronchial endoscopy with bronchoalveolar lavage (LBA)Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
DIAGNOSTIC_TESTBlood samplingcollection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay

Timeline

Start date
2022-06-01
Primary completion
2024-06-01
Completion
2024-06-01
First posted
2022-05-06
Last updated
2024-04-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05364996. Inclusion in this directory is not an endorsement.